Novartis India Moves On From Glivec Patent Loss To Launch More Drugs
This article was originally published in PharmAsia News
Executive Summary
Novartis India, which lost a patent battle for its cancer drug Glivec (imatinib) a year ago, has shaken off the loss and launched drugs in India along with more than a dozen generics in the interim.